CN117597348A - 用于治疗诸如癌症的疾病的(r)-n-乙基-5-氟-n-异丙基-2-((5-(2-(6-((2-甲氧基乙基)(甲基)氨基)-2-甲基己-3-基)-2,6-二氮杂螺[3.4]辛-6-基)-1,2,4-三嗪-6-基)氧基)苯甲酰胺苯磺酸盐 - Google Patents
用于治疗诸如癌症的疾病的(r)-n-乙基-5-氟-n-异丙基-2-((5-(2-(6-((2-甲氧基乙基)(甲基)氨基)-2-甲基己-3-基)-2,6-二氮杂螺[3.4]辛-6-基)-1,2,4-三嗪-6-基)氧基)苯甲酰胺苯磺酸盐 Download PDFInfo
- Publication number
- CN117597348A CN117597348A CN202280043068.0A CN202280043068A CN117597348A CN 117597348 A CN117597348 A CN 117597348A CN 202280043068 A CN202280043068 A CN 202280043068A CN 117597348 A CN117597348 A CN 117597348A
- Authority
- CN
- China
- Prior art keywords
- compound
- leukemia
- ethyl
- fluoro
- diazaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410890382.3A CN118852178A (zh) | 2021-06-17 | 2022-06-16 | 用于治疗诸如癌症的疾病的化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021100466 | 2021-06-17 | ||
| CNPCT/CN2021/100466 | 2021-06-17 | ||
| CN2022091677 | 2022-05-09 | ||
| CNPCT/CN2022/091677 | 2022-05-09 | ||
| PCT/CN2022/099089 WO2022262796A1 (en) | 2021-06-17 | 2022-06-16 | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410890382.3A Division CN118852178A (zh) | 2021-06-17 | 2022-06-16 | 用于治疗诸如癌症的疾病的化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117597348A true CN117597348A (zh) | 2024-02-23 |
Family
ID=82196389
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280043068.0A Pending CN117597348A (zh) | 2021-06-17 | 2022-06-16 | 用于治疗诸如癌症的疾病的(r)-n-乙基-5-氟-n-异丙基-2-((5-(2-(6-((2-甲氧基乙基)(甲基)氨基)-2-甲基己-3-基)-2,6-二氮杂螺[3.4]辛-6-基)-1,2,4-三嗪-6-基)氧基)苯甲酰胺苯磺酸盐 |
| CN202410890382.3A Pending CN118852178A (zh) | 2021-06-17 | 2022-06-16 | 用于治疗诸如癌症的疾病的化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410890382.3A Pending CN118852178A (zh) | 2021-06-17 | 2022-06-16 | 用于治疗诸如癌症的疾病的化合物 |
Country Status (16)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12473295B2 (en) | 2019-12-19 | 2025-11-18 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250170131A (ko) | 2023-04-17 | 2025-12-04 | 얀센 파마슈티카 엔브이 | 조혈 장애를 치료하기 위한 메닌-ll1 억제제, dna 삽입제 및 피리미딘 유사체의 조합물 |
| KR20260099138A (ko) | 2023-10-20 | 2026-06-26 | 얀센 파마슈티카 엔브이 | 암 치료에 사용하기 위한, (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드, 이의 제제 및 이의 투여 요법 |
| KR20260115654A (ko) | 2023-12-04 | 2026-07-24 | 쇼우야오 홀딩스 (베이징) 코., 엘티디. | 치환된 다환 화합물 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010289321A1 (en) | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| AU2014249233A1 (en) | 2013-03-13 | 2015-09-24 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
| BR112018012707A2 (pt) * | 2015-12-22 | 2019-01-29 | Vitae Pharmaceuticals Inc | inibidores da interação de menin-mll |
| AU2017212572A1 (en) | 2016-01-26 | 2018-08-23 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| US10752639B2 (en) | 2016-03-16 | 2020-08-25 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| CN109415337B (zh) | 2016-05-02 | 2022-01-18 | 密执安大学评议会 | 作为多发性内分泌腺瘤蛋白抑制剂的哌啶 |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| TWI753016B (zh) | 2016-09-14 | 2022-01-21 | 比利時商健生藥品公司 | Menin-mll相互作用之稠合二環抑制劑 |
| CN118359610A (zh) | 2016-09-16 | 2024-07-19 | 生命医药有限责任公司 | Menin-mll相互作用的抑制剂 |
| WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
| JP2022503792A (ja) | 2018-09-26 | 2022-01-12 | クラ オンコロジー,インク. | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| UY38988A (es) | 2019-12-19 | 2021-06-30 | Janssen Pharmaceutica Nv | Derivados espiráncos sustituidos de cadena lineal |
-
2022
- 2022-06-16 AU AU2022292697A patent/AU2022292697A1/en active Pending
- 2022-06-16 KR KR1020237043027A patent/KR20240021808A/ko active Pending
- 2022-06-16 MX MX2023014890A patent/MX2023014890A/es unknown
- 2022-06-16 EP EP22733288.9A patent/EP4355747A1/en active Pending
- 2022-06-16 CN CN202280043068.0A patent/CN117597348A/zh active Pending
- 2022-06-16 JP JP2023576415A patent/JP7864745B2/ja active Active
- 2022-06-16 CA CA3220099A patent/CA3220099A1/en active Pending
- 2022-06-16 CN CN202410890382.3A patent/CN118852178A/zh active Pending
- 2022-06-16 PE PE2023003361A patent/PE20240923A1/es unknown
- 2022-06-16 WO PCT/CN2022/099089 patent/WO2022262796A1/en not_active Ceased
- 2022-06-16 PH PH1/2023/553300A patent/PH12023553300A1/en unknown
- 2022-06-16 US US18/570,727 patent/US20260125387A1/en active Pending
- 2022-06-16 IL IL309359A patent/IL309359A/en unknown
- 2022-06-17 UY UY0001039823A patent/UY39823A/es unknown
-
2023
- 2023-11-28 DO DO2023000260A patent/DOP2023000260A/es unknown
- 2023-12-13 CL CL2023003731A patent/CL2023003731A1/es unknown
- 2023-12-28 CO CONC2023/0018577A patent/CO2023018577A2/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12473295B2 (en) | 2019-12-19 | 2025-11-18 | Janssen Pharmaceutica Nv | Substituted straight chain spiro derivatives |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202315636A (zh) | 2023-04-16 |
| WO2022262796A1 (en) | 2022-12-22 |
| KR20240021808A (ko) | 2024-02-19 |
| CL2023003731A1 (es) | 2024-07-05 |
| PH12023553300A1 (en) | 2024-04-08 |
| IL309359A (en) | 2024-02-01 |
| CO2023018577A2 (es) | 2024-01-15 |
| UY39823A (es) | 2023-01-31 |
| JP7864745B2 (ja) | 2026-05-25 |
| MX2023014890A (es) | 2024-04-29 |
| AU2022292697A1 (en) | 2024-02-01 |
| US20260125387A1 (en) | 2026-05-07 |
| WO2022262796A8 (en) | 2023-03-23 |
| JP2024525145A (ja) | 2024-07-10 |
| CN118852178A (zh) | 2024-10-29 |
| DOP2023000260A (es) | 2024-05-15 |
| CA3220099A1 (en) | 2022-12-22 |
| EP4355747A1 (en) | 2024-04-24 |
| PE20240923A1 (es) | 2024-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7781961B2 (ja) | 置換直鎖スピロ誘導体 | |
| CN118852178A (zh) | 用于治疗诸如癌症的疾病的化合物 | |
| KR20210105375A (ko) | Cdk 저해제로서의 대환식 화합물, 이의 제조 방법, 및 의약에서의 이의 용도 | |
| KR20190032613A (ko) | (s)-7-(1-아크릴로일피페리딘-4-일)-2-(4-페녹시페닐)-4,5,6,7-테트라-하이드로피라졸로 [1,5-a] 피리미딘-3-카르복스아미드의 제조 및 그 용도 | |
| IL191776A (en) | Carbonylamino pyrrolopyrazole compounds , pharmaceutical compositions comprising them and use of the compounds in the preparation of medicaments | |
| EA011815B1 (ru) | Пирролопиразолы в качестве сильнодействующих ингибиторов киназы | |
| EP1515965B1 (de) | Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren | |
| RS60680B1 (sr) | Piperidin-4-il azetidin derivati kao inhibitori jak1 | |
| CN117425659A (zh) | 哒嗪或被螺环胺取代的1,2,4-三嗪 | |
| HK40101887A (en) | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer | |
| HK40117713A (en) | Compound useful for treating diseases such as cancer | |
| EP3915990A1 (en) | 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-3,6-dihydropyridine-1-(2h)-carboxamide derivatives as limk and/or rock kinases inhibitors for use in the treatment of cancer | |
| CN115232122B (zh) | 炔类化合物及其制备和应用 | |
| EA050953B1 (ru) | Безилатная соль (r)-n-этил-5-фтор-n-изопропил-2-((5-(2-(6-((2-метоксиэтил)(метил)амино)-2-метилгексан-3-ил)-2,6-диазаспиро[3,4]октан-6-ил)-1,2,4-триазин-6-ил)окси)бензамида для лечения заболеваний, таких как рак | |
| HK40113255A (en) | Substituted straight chain spiro derivatives | |
| HK40071760A (en) | Substituted straight chain spiro derivatives | |
| HK40113268A (en) | Kif18a inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40101887 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |